Green OA Is Golden

A new report lauds the UK government’s commitment to open access, but calls its early devotion to the gold model a “mistake.”

Written byTracy Vence
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, PLOSThe British government’s commitment to increasing public access to published research is a worthy but expensive cause, according to a report out today (September 10) from the House of Commons’ Business, Innovation and Skills (BIS) Committee. The group noted in a statement that while the “gold” model of open access (OA)—in which project funders, and not study authors, cover publishing costs—is “a desirable ultimate goal, focusing on it during the transition to a fully open access world is a mistake.”

In its report, the BIS committee called on the government and the United Kingdom Research Councils (RCUK) to reconsider their preference for gold OA during the move to open access. “For the U.K. to transition to open access, an effective, functioning, and competitive market in scholarly communications will be vital,” the committee noted. “The evidence we saw over the course of this inquiry shows that this is currently far from the case, with journal subscription prices rising at rates that are unsustainable for UK universities and other subscribers.” The BIS committee added that, as it stands, the government’s open access policy might actually “encourage and prolong the dysfunctional elements of the scholarly publishing market.”

“The reason we have set a clear preference for gold open ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies